In a subgroup analysis, patients with HPVDNA+ OSCC with an absence of or weak HLA class I intensity staining generally presented a better clinical outcome than those with OSCC with a strong tumor HLA class I expression, irrespectively of p16INK4a status. This evidence concerns the gene CDKN2A and neoplasm.